Modeling Study Published in Clinical Gastroenterology and Hepatology Validates Geneoscopy's ColoSense® Real-World Screening Impact
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the publication of a new study in Clinical Gastroenterology and Hepatology showing that its FDA-approved multitarget stool RNA (mt-sRNA) test, ColoSense®, achieved notable clinical benefits among colorectal cancer (CRC) screening tests when modeled at real-world adherence levels.
In the absence of a head-to-head study comparing CRC screening options, this peer-reviewed modeling study, titled 'Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia,' provides valuable insights by evaluating five CRC screening strategies for patients aged 45 and older. Using a 10-year Markov model, researchers simulated disease progression, comparing mt-sRNA, two mt-sDNA tests, a blood-based test, and a fecal immunochemical test (FIT), and reported findings similar to previously published modeling studies. 1-3 When test performance was normalized to better reflect the age of the intended use population, the clinical and economic benefits of ColoSense were amplified.
At real-world adherence of 60% (the typical rate observed in practice), the modeling study results showed that ColoSense reduced CRC deaths by 14% compared to FIT, by 19% and 23% compared to the mt-sDNA tests, and by 86% compared to a blood-based test. 1 While FIT remained the most cost-effective strategy overall, ColoSense was the most cost-effective among molecular tests across all levels of screening adherence.
'Study cohorts often don't reflect the target patient population, which can skew results and limit clinical relevance,' said Dr. Erica Barnell, co-author and Chief Science and Medical Officer at Geneoscopy. 'These data reinforce the need to design studies around real-world populations. ColoSense was developed with that in mind, delivering strong performance across diverse groups, including younger adults who are often under-represented in clinical trials.'
This study builds on prior research by using a model that normalizes the age of the populations in independent, peer-reviewed studies to better reflect the general screening population. Given that many assays rely on methylation-based biomarkers, whose sensitivity is lower in younger individuals, 4,5 adjusting sensitivity estimates for colorectal cancer and advanced adenomas is essential for accurate clinical and economic assessment.
ColoSense is included in the 2025 National Comprehensive Cancer Network (NCCN) guideline update, highlighting the strength of its clinical evidence and the robust science behind Geneoscopy's RNA-based approach. As the only FDA-approved stool RNA test for CRC screening, ColoSense represents a significant step forward in noninvasive screening methods, underscoring the need for accessible alternatives that can increase compliance, especially among groups less likely to pursue colonoscopy.
*All data used in the study were derived from independent, non-head-to-head clinical trial results.
About ColoSense
ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.
A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA) in October 2023. For more information, visit www.colosense.com.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
References
View source version on businesswire.com:https://www.businesswire.com/news/home/20250624950274/en/
CONTACT: Media Contact
Andrea Sampson
Sampson Public Relations Group
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MISSOURI
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH MANAGED CARE ONCOLOGY HEALTH GENETICS CLINICAL TRIALS
SOURCE: Geneoscopy, Inc.
Copyright Business Wire 2025.
PUB: 06/24/2025 08:05 AM/DISC: 06/24/2025 08:04 AM
http://www.businesswire.com/news/home/20250624950274/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
Yahoo
32 minutes ago
- Yahoo
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging
Business Wire
an hour ago
- Business Wire
New Survey: College Students Feel Coerced Into Participating in Animal Experiments Despite Objections; 83% Oppose Such Exercises
WASHINGTON--(BUSINESS WIRE)--Eighty-three percent of U.S. college students believe that animals should not be used in classroom teaching laboratories if the animals are killed afterward and if other methods can teach the same material without using animals, according to a new OpinionWorks survey. Among those majoring in the sciences, 90% believe animals should not be used. The survey, which was conducted online among 1,043 U.S. undergraduate college students from Aug. 8 to 10, 2025, also posed the hypothetical scenario in which such an animal laboratory was offered as an optional experience, along with a nonanimal alternative. In that case, although most students did not want to participate, 20% stated they would do so anyway to avoid problems, and another 24% stated that they would be nervous asking for the alternative activity. The survey also found an overwhelming majority of students, 79%, expressed concern about the welfare of animals. 'The vast majority of college students don't want to participate in deadly animal experiments in the classroom but feel subtly coerced because they are fearful of the consequences of not taking part,' says Neal Barnard, MD, president of the Physicians Committee for Responsible Medicine. 'Colleges with old-fashioned animal labs put students in an awful position that many interpret as a choice between killing or flunking.' The survey results arrive amid an ongoing lawsuit against fatal animal experiments at Macalester College in Saint Paul, Minn., where students will begin arriving for the new school year on Aug. 25. In psychology courses at Macalester, live animals are deprived of water for prolonged periods, then placed in 'Skinner boxes,' where they have to work for water. Some experiments involve drugging animals and placing them in mazes. All are killed at the conclusion of the experiments. Harvard, Yale, Stanford, Princeton, and other leading universities stopped the Macalester-style fatal experiments long ago. The new survey found that 76% of college students do not approve of the use of live animals in psychology classes when the animals are killed afterward and when there are alternative teaching methods. Macalester's website says that its 'animal welfare standards and ethical principles are applied at the highest possible level in any animal use or research conducted at or in association with the college' and that it follows the federal Animal Welfare Act, which incorporates ethical principles called the Three Rs—for the replacement, reduction, and refinement of animal use in research. A lawsuit against Macalester, brought by alumnus Dr. Barnard on June 3, calls on the college to stop needlessly killing animals in psychology classes' 'show and tell' exercises, citing the college's posted ethics commitment. The psychology department has killed thousands of animals for more than 50 years. The college stated in its motion to dismiss, which Dr. Barnard responded to in court papers, that its own ethics statements are mere 'generic phrases'—known legally as 'puffery.' The college wrote, 'These statements are, at most, 'vague or highly subjective' statements of superiority—not representations of material fact,' drawing comparisons with statements used to sell dog food or breakfast cereal. 'Given that animals' lives are at stake, Macalester's brazen statement that it did not really mean its ethics policy is an affront to students, donors, the faculty, and the public,' Dr. Barnard said. The lawsuit seeks, among other actions, an order compelling Macalester 'to cease its use of animal laboratories in psychology instruction and in all other areas for which nonanimal methods are available.' To speak with Dr. Barnard, please contact Michael Keevican at 202-527-7367 or mkeevican@ Founded in 1985, the Physicians Committee for Responsible Medicine is a nonprofit organization that promotes preventive medicine, conducts clinical research, and encourages higher standards for ethics and effectiveness in education and research.
